Although substantial progress has been made over the past 40 years in treating patients
with cancer, effective therapies for those who are diagnosed with advanced metastatic …

Pancreatic ductal adenocarcinoma (PDAC) is a hostile solid malignancy coupled with an
extremely high mortality rate. Metastatic disease is already found in most patients at the time …

Metastasis is still poorly understood and thus further research must be conducted to provide
insight into the driving factors. Novel research has revealed the significance of the …

Recent evidence indicates that the plasticity of preexisting hepatocytes and bile duct cells is
responsible for the appearance of intermediate progenitor cells capable of restoring liver …

Prostate cancer (PCa) is the second most diagnosed type of cancer in men worldwide.
Advanced PCa is resistant to conventional therapies and high recurrence has been …

Breast cancer is the most common malignant disease in female patients worldwide and can
spread to almost every place in the human body, most frequently metastasizing to lymph …

Pancreatic ductal adenocarcinoma (PDAC) is commonly diagnosed when liver metastases
already emerged. We recently demonstrated that hepatic stromal cells determine the …

Radiodynamic therapy (RDT) is an emerging non-invasive anti-cancer treatment based on
the generation of the reactive oxygen species (ROS) at the lesion site following the …

The goal of successful cancer treatment is targeting the eradication of cancer cells. Although
surgical removal of the primary tumors and several rounds of chemo-and radiotherapy …

Pancreatic ductal adenocarcinoma (PDAC) is one of the most malignant cancers. It is
characterized by a poor prognosis with a 5-year survival rate of only around 10% and an …